Press Releases

Atreca Appoints Clinical Development Leader Lori Kunkel, M.D., as a Technical Advisor

July 19, 2016

REDWOOD CITY, Calif. — Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced today the appointment of Lori Kunkel, M.D, as a technical Advisor. Dr. Kunkel has an esteemed track record in development of clinical and regulatory strategies resulting in the global commercialization of successful oncology products.

“Dr. Kunkel brings industry-leading expertise that will play a critical role as Atreca advances its lead immuno-oncology programs into the clinic,” said Lawrence Steinman, M.D., Co-Founder and Director of Atreca, and the George A. Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics in the Stanford University School of Medicine. “We are thrilled that she is joining us as an Advisor at this important time for the company.”

“Lori is a highly accomplished life sciences executive with deep knowledge in oncology drug development,” said Tito A. Serafini, Ph.D., Atreca’s President, Chief Executive Officer, and CoFounder. “We believe her insights and advice will be invaluable to the progress of our proprietary pipeline generated via our Immune Repertoire Capture™ (IRC™) technology.”

Dr. Kunkel has led successful clinical development programs at several life sciences companies, most recently as Chief Medical Officer at Pharmacyclics (acquired by AbbVie) and Proteolix, Inc. (acquired by Onyx Pharmaceuticals), which ultimately resulted in the global approvals of cancer therapeutics IMBRUVICA® and Kyprolis®, respectively. Prior to this, she was Vice President of Clinical Development at Xencor, Inc. Dr. Kunkel began her career in industry as a clinical scientist at Genentech working on the development of RITUXAN®. Additionally, Dr. Kunkel has advised multiple firms, including Chiron (acquired by Novartis), Genentech/Roche, Salmedics (acquired by Celgene), and Syndax, and currently is an advisor to Curis, Inc., and Stemcentrx, Inc. She also serves on the boards of directors of Amphivena Therapeutics, Tocagen, Inc., Harpoon Therapeutics, and Loxo Oncology. Prior to entering the biotechnology industry, Dr. Kunkel spent ten years in academic medicine, during which time she served as Director of the Lymphoma Division in the Division of Hematology/Oncology at University of California, Los Angeles. She obtained her bachelor’s degree in biology from University of California, San Diego, and her M.D. degree from the University of Southern California. She is board-certified in internal medicine and held board certifications in hematology and oncology.

“I am excited about the opportunity to work with the talented team at Atreca,” commented Dr. Kunkel. “I believe the Company holds great potential in identifying novel therapeutic agents and treatment paradigms for immunotherapy approaches in oncology. I look forward to helping drive progress at Atreca.”

About Atreca, Inc.

Atreca is a privately held biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-cancer immune responses. We are able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atreca’s proprietary Immune Repertoire Capture™ technology profiles a patient’s immune response at the single-cell level at very high throughput without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates with the objective of enhancing engagement of the human immune response in cancer treatment and other indications, thus optimizing therapeutic outcomes. For more information on Atreca, please visit


Atreca, Inc.:
Susan Berland EVP and Chief Financial Officer


Media: Justin Jackson, 212-213-0006, ext. 327